Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1) (MicroB1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02124759 |
Recruitment Status :
Completed
First Posted : April 28, 2014
Results First Posted : October 15, 2021
Last Update Posted : October 15, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Sensitivity | Drug: Sevelamer Drug: Synbiotic Drug: Maltodextrin Other: High Fat diet Other: Low Fat diet | Phase 2 |
We will test the hypothesis that a high fat diet given to lean, normal glucose tolerant subjects will impair insulin signaling and sensitivity and modify gut microbiome composition and enhance intestinal permeability, which will increase plasma LPS concentration, induce an inflammatory response in peripheral tissues (skeletal muscle). Also we will test the hypothesis that the inflammatory response and insulin resistance caused by high fat ingestion can be ameliorated by administering
- a synbiotic (Bifidobacterium longum R0175 and oligofructose) which protects the intestinal epithelial barrier and decreases intestinal translocation of LPS; and
- sevelamer, an agent which sequesters lipopolysaccharide (LPS) in the gastrointestinal tract limiting its translocation into the circulation.
All subjects are fed both a low fat diet (considered a normal diet) and high fat diet, first one and then the other in no particular sequence. After a washout period participants are fed the other type of high or low fat diet, depending on which diet they were first assigned to in order to compare the effects of the intervention on insulin sensitivity during each diet.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1) |
Actual Study Start Date : | April 2, 2014 |
Actual Primary Completion Date : | February 23, 2018 |
Actual Study Completion Date : | March 30, 2020 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Placebo: maltodextrin, 6 g three times a day
|
Drug: Maltodextrin
This is a control group. Maltodextrin, 6 g three times a day Other: High Fat diet The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
Other Name: Isocaloric high fat diet Other: Low Fat diet The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
Other Name: Isocaloric low fat (normal) diet |
Active Comparator: Sevelamer
Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
|
Drug: Sevelamer
1.6 g sevelamer + 4.4 g maltodextrin three times a day
Other Name: Renvela Other: High Fat diet The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
Other Name: Isocaloric high fat diet Other: Low Fat diet The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
Other Name: Isocaloric low fat (normal) diet |
Active Comparator: Synbiotic
Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
|
Drug: Synbiotic
5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day. Other: High Fat diet The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
Other Name: Isocaloric high fat diet Other: Low Fat diet The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
Other Name: Isocaloric low fat (normal) diet |
- Insulin Sensitivity Low Fat Diet [ Time Frame: Day 28 ]Skeletal muscle insulin sensitivity measured after 28 days of low fat diet and drug intervention. The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
- Insulin Sensitivity High Fat Diet [ Time Frame: Day 28 ]Skeletal muscle insulin sensitivity measured after 28 days of high fat diet. The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
- Plasma Endotoxin Levels [ Time Frame: At baseline, on day 3, and 28 of the intervention. ]Endotoxin is a bacterially derived product that we hypothesized would impact insulin sensitivity through pro inflammatory pathways.
- Gut Permeability [ Time Frame: on Day 24 of the intervention. ]Gut permeability is measured using a lactulose/mannitol ingestion assay where urine samples are collected to analyse the ratio of excreted lactulose:mannitol.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Both genders. All races and ethnic groups.
- Premenopausal women in the follicular phase, non-lactating, and with a negative pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone replacement for ≥6 months.
- Hematocrit (HCT)≥ 34%, serum creatinine ≤ 1.4 mg/dl, and normal serum electrolytes, urinalysis, and coagulation tests. Liver function tests (LFTs) up to 2 times normal.
- Stable body weight (±2%) for ≥ 3 months
- Two or less sessions of strenuous exercise/wk for last 6 months.
Exclusion Criteria:
- Presence of diabetes or impaired glucose tolerance based on ADA criteria.
- Current treatment with drugs known to affect glucose and lipid homeostasis. If the subject has been on a stable dose for the past 3 months, the following agents will be permitted: calcium channel blockers, β-blockers, ACE inhibitors, angiotensin receptor blockers, and statins
- History of allergy to sevelamer.
- History of Non-steroidal anti-inflammatory drugs or systemic steroid use for more than a week within 3 months.
- Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and clopidogrel will be permitted if these can be held for seven days prior to the biopsy in accordance with the primary physician.
- Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG) within 3 months.
- History of heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease, pulmonary disease, smokers.
- Poorly controlled blood pressure (systolic BP>170, diastolic BP>95 mmHg).
- Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and psychiatric disease.
- History of gastrointestinal surgery or gastrointestinal obstruction within two years.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02124759
United States, Texas | |
Audie L. Murphy VA Hospital, STVHCS | |
San Antonio, Texas, United States, 78229 |
Principal Investigator: | Nicolas Musi, MD. | The University of Texas Health Science Center at San Antonio |
Documents provided by The University of Texas Health Science Center at San Antonio:
Responsible Party: | The University of Texas Health Science Center at San Antonio |
ClinicalTrials.gov Identifier: | NCT02124759 |
Other Study ID Numbers: |
HSC20130459H IRB #20130458H ( Other Grant/Funding Number: American Diabetes Association ) |
First Posted: | April 28, 2014 Key Record Dates |
Results First Posted: | October 15, 2021 |
Last Update Posted: | October 15, 2021 |
Last Verified: | September 2021 |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Sevelamer Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |